Before its IPO, Anthropic plays its research card: Claude "autonomously discovers" a CRISPR-like system, and the gene-editing sector is hit by "AI replacement anxiety."

Zhito Finance APP has learned that on Wednesday, shares of U.S. gene-editing companies moved lower. Previously, Anthropic announced that its AI model Claude "autonomously discovered" a new type of enzyme system similar to the gene-editing tool CRISPR.